COMMUNIQUÉS West-GlobeNewswire

Zevra Therapeutics to Present at the Citizens Life Sciences Conference
25/02/2026
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Effective Oral Steroids For Strength & Muscle Growth 2026: Legal Steroids For Sale" Smart Bodybuilders Use Crazy Bulk Steroid Alternatives.
25/02/2026
Legal Steroids For Sale 2026: Launched By Crazy Bulk" Steroids Alternatives for Cutting, Bulking, Body Building & Muscle Growth Safe Oral Steroids For Strength in USA. New York City, Feb. 25, 2026 (GLOBE NEWSWIRE [...]
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
25/02/2026
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE [...]
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
25/02/2026
Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous [...]
Upstream Bio to Participate in Upcoming March Investor Conferences
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
25/02/2026
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
25/02/2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Axsome Therapeutics to Participate in Upcoming Investor Conferences
25/02/2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it [...]
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies [...]
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
25/02/2026
BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the [...]
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
25/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney [...]
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
25/02/2026
SAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Aura Biosciences to Participate in Upcoming Investor Conferences
25/02/2026
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today [...]
Ovid Therapeutics to Participate in Upcoming Investor Conferences
25/02/2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural [...]
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
25/02/2026
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
25/02/2026
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating [...]
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
25/02/2026
Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market [...]
Helsinn Healthcare & InVirtuoLabs sign a Strategic Collaboration in AI-Driven Drug Discovery
25/02/2026
Partnership combines Helsinn proprietary compound library with InVirtuoLabs generative AI platform to accelerate discovery of novel therapeutics Lugano, Switzerland – February 25, 2026 – Helsinn Healthcare SA (Helsinn [...]
Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
25/02/2026
Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys Data published in the American Journal of [...]

Pages